Table 1. Patient characteristics .... | American Society of Hematology

Table 1.

Patient characteristics

	Diagnosis CP-CML	Pre-MMR	MMR	MR^4.5	TFR
BCR-ABL1	≥10%	>0.1%, <10%	≤0.1%, >0.0032%	≤0.0032%*	0%
Patients, n	21	8	20	16	13
Age at diagnosis, median (range), y	52 (34-85)	NA	NA	NA	NA
Sex, %
Male	52	62	67	56	46
Female	48	38	33	44	54
TKI duration, median (range), mo	0	12.5 (3-31)	36 (5-132)	31 (8-150)	NA†
TKI therapy, %
Imatinib	NA	50	48	65	NA
Nilotinib	NA	38	37	22	NA
Dasatinib	NA	12	15	13	NA

	Diagnosis CP-CML	Pre-MMR	MMR	MR^4.5	TFR
BCR-ABL1	≥10%	>0.1%, <10%	≤0.1%, >0.0032%	≤0.0032%*	0%
Patients, n	21	8	20	16	13
Age at diagnosis, median (range), y	52 (34-85)	NA	NA	NA	NA
Sex, %
Male	52	62	67	56	46
Female	48	38	33	44	54
TKI duration, median (range), mo	0	12.5 (3-31)	36 (5-132)	31 (8-150)	NA†
TKI therapy, %
Imatinib	NA	50	48	65	NA
Nilotinib	NA	38	37	22	NA
Dasatinib	NA	12	15	13	NA

NA = not applicable.

15/16 (93.7%) patients had undetectable BCR-ABL1 transcripts at time of sample collection.

TFR patients have been off TKIs for a median of 6 months (range, 3-22 months).